NEWS
Atelerix signs agreement with CliniSciences to ...
Atelerix has entered a distribution agreement with CliniSciences to expand access to its cryo-free, hydrogel-based cell preservation solutions across Europe and North Africa. The partnership will strengthen Atelerix’s regional reach...
Atelerix signs agreement with CliniSciences to ...
Atelerix has entered a distribution agreement with CliniSciences to expand access to its cryo-free, hydrogel-based cell preservation solutions across Europe and North Africa. The partnership will strengthen Atelerix’s regional reach...
Spotlight on Researchers Using Organoids in Dis...
Organoids are transforming disease modelling by capturing the complexity of human biology in ways that traditional systems cannot, with pioneers in academia, biotech, and CROs already driving breakthroughs. This spotlight...
Spotlight on Researchers Using Organoids in Dis...
Organoids are transforming disease modelling by capturing the complexity of human biology in ways that traditional systems cannot, with pioneers in academia, biotech, and CROs already driving breakthroughs. This spotlight...
Atelerix and Rodon Global partner to integrate ...
By integrating Atelerix’s unique cryo-free preservation products within Rodon’s dynamic logistics offering, the collaboration will significantly broaden access to safe shipping and storage solutions for temperature-sensitive biomaterials, without freezing. Samples...
Atelerix and Rodon Global partner to integrate ...
By integrating Atelerix’s unique cryo-free preservation products within Rodon’s dynamic logistics offering, the collaboration will significantly broaden access to safe shipping and storage solutions for temperature-sensitive biomaterials, without freezing. Samples...
Overcoming Organoid Preservation Challenges in ...
Contract Research Organisations are turning to organoids to deliver more predictive models for drug discovery and toxicology studies. Atelerix’s WellReady™ technology allows these fragile 3D systems to be preserved at...
Overcoming Organoid Preservation Challenges in ...
Contract Research Organisations are turning to organoids to deliver more predictive models for drug discovery and toxicology studies. Atelerix’s WellReady™ technology allows these fragile 3D systems to be preserved at...
From Lab to Market: Recent Advances and Commerc...
Organoids are transforming biomedical research, offering human-relevant models that surpass traditional 2D cell cultures and animal testing. With rapid advances in bioprinting, organ-on-a-chip integration, and regulatory endorsement, organoids are moving...
From Lab to Market: Recent Advances and Commerc...
Organoids are transforming biomedical research, offering human-relevant models that surpass traditional 2D cell cultures and animal testing. With rapid advances in bioprinting, organ-on-a-chip integration, and regulatory endorsement, organoids are moving...
Sunil Shah and Dr Catherine Elton join Atelerix...
Atelerix is delighted to welcome Sunil Shah as Chair and Dr Catherine Elton as Non-Executive Director to help drive the company’s global expansion of its pioneering non-cryogenic cell preservation technology.
Sunil Shah and Dr Catherine Elton join Atelerix...
Atelerix is delighted to welcome Sunil Shah as Chair and Dr Catherine Elton as Non-Executive Director to help drive the company’s global expansion of its pioneering non-cryogenic cell preservation technology.
